Met DR

DRUG5 trials

Sponsors

Elcelyx Therapeutics, Inc.

Conditions

Healthy SubjectsRenal InsufficiencyType 2 Diabetes Mellitus

Phase 1

Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM

CompletedNCT01804842

Elcelyx Therapeutics, Inc.Type 2 Diabetes Mellitus

Start: 2012-12-31End: 2013-04-30Updated: 2016-10-21

Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

CompletedNCT02291510

Elcelyx Therapeutics, Inc.Healthy Subjects

Start: 2012-10-31End: 2012-12-31Updated: 2016-12-02

Phase 2

Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction

CompletedNCT01658514

Elcelyx Therapeutics, Inc.Renal Insufficiency

Start: 2014-01-31End: 2014-06-30Updated: 2015-12-30

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

CompletedNCT01819272

Elcelyx Therapeutics, Inc.Type 2 Diabetes Mellitus

Start: 2013-04-30End: 2013-09-30Updated: 2017-03-15

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

CompletedNCT02526524

Elcelyx Therapeutics, Inc.Type 2 Diabetes Mellitus

Start: 2015-09-30End: 2016-09-30Updated: 2018-04-27

Related Papers

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

UNC Libraries2020-04-16

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

PLoS ONE2018-09-2534 citations

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.

2016-05-2394 citations